Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
70 participants
INTERVENTIONAL
2024-11-06
2025-06-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main aims of this study are:
* To evaluate the feasibility and acceptability of the LMH-4-DCP platform.
* To explore the potential for LMH-4-DCP to reduce feelings of pre-loss grief and enhancing relationship quality in dementia family caregivers and their care-recipients ('Care-Pairs')
Care pair participants will be asked to log-in to LMH-4-DCP and complete study activities three times per week for two weeks. Researchers will compare the intervention group to an attention control condition to see if LMH-4-DCP's use is associated with reduced feelings of caregiver pre-loss grief and improved care pair relationship quality at follow-up.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dementia Family Caregiver Study
NCT04894006
A Non-pharmacological Intervention for Patients With Alzheimer's Disease and Family Caregivers (Care Partners Program)
NCT03333252
Assistive Technology and Reduced Caregiver Burden
NCT05352529
Home-Based Assessment for Alzheimer Disease Prevention
NCT00546767
Dementia Caregiver Chronic Grief Management: A Live Online Video Intervention
NCT03593070
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main aims of this study are:
* To evaluate the feasibility and acceptability of the LMH-4-DCP platform.
* To explore the influence of the LMH-4-DCP intervention on reducing feelings of pre-loss grief and enhancing relationship quality in the care pair
Caregiver participants randomized to the intervention condition will be asked to log-in to LMH-4-DCP and complete reminiscence activities three times per week for two weeks. Researchers will compare the intervention group to an attention control condition, which includes LMH-4-DCP use without reminiscence-specific features, to see if LMH-4-DCP's use is associated with reduced feelings of caregiver pre-loss grief and improved care pair relationship quality at follow-up.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LMH-4-DCP Intervention
LMH-4-DCP
Reminiscence-based intervention for family caregiver-Persons with Dementia (PwD) dyads to record and reflect on meaningful memories to address family caregivers' pre-loss grief and enhance relationship quality.
Attention Control Arm
LMH-4-DCP access without reminiscence activities
Participants in the attention control condition will have access to a version of LMH-4-DCP excluding reminiscence-specific activities.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LMH-4-DCP
Reminiscence-based intervention for family caregiver-Persons with Dementia (PwD) dyads to record and reflect on meaningful memories to address family caregivers' pre-loss grief and enhance relationship quality.
LMH-4-DCP access without reminiscence activities
Participants in the attention control condition will have access to a version of LMH-4-DCP excluding reminiscence-specific activities.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* be a primary source of care for a family member in the early to moderate stages of dementia
* 18 years of age or older
* English-speaking
* able to use the internet and has internet access
* residing in the United States
Exclusion Criteria
* under the age of 18-years-old
* exhibits cognitive impairment (by scoring 3 or more on the SPMSQ)
* does not speak English as a primary language.
* severe cognitive impairment detected by the clinical or study staff using validated, brief screening tools (e.g., a score of 8 errors or more on the SPMSQ)
* does not demonstrate capacity to consent (e.g., a score of 9 or fewer errors on the University of California-San Diego Brief Assessment of Capacity to consent
* PwD is living in a long-term care facility
* does not speak English as a primary language
* is under the age of 18 years old.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
Weill Medical College of Cornell University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Holly Prigerson, PhD
Role: PRINCIPAL_INVESTIGATOR
Weill Medical College of Cornell University
Francesca Falzarano, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Southern California; Weill Cornell Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Weill Cornell Medicine
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-07026251
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.